Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Stora Enso publishes its Annual Report 2023

STORA ENSO OYJ ANNUAL FINANCIAL REPORT 13 February 2024 at 9:30 EETStora Enso’s Annual Report 2023 is published today at storaenso.com/annualreport .  The report includes a strategy review, sustainability reporting, corporate governance, remuneration report and financial report.   Stora Enso publishes its annual financial statements in accordance with the European Single Electronic Format (ESEF) reporting requirements. The format of the report is Extensible Hypertext Markup Language (xHTML). In line with the ESEF requirements, the

Cline Scientific advisor discusses the future of cartilage damage treatment

A video interview featuring Professor Mats Brittberg, senior physician in orthopedics at Varberg Hospital and Professor at the University of Gothenburg talks about future treatments for cartilage damage has been published.Mats Brittberg, senior physician in orthopedics at Varberg Hospital and professor at the University of Gothenburg, is a scientific advisor to Cline Scientific. In the video published by BioStock, Brittberg discusses future treatments for cartilage damage and osteoarthritis. Brittberg highlights Cline's StemCART project and the work we are doing to develop an allogeneic

Genovis to receive USD 1 million in milestone compensation related to the development of the Xork™ enzyme

The milestone compensation is related to achieved development targets for the Xork enzyme that Genovis has out-licensed for therapeutic applications, primarily as a potential pre-treatment in gene therapy but also for autoimmune diseases.Xork is derived from a streptococcal bacterial strain that does not infect humans. The pre-clinical data generated to date highlights Xork’s differentiated profile demonstrating very low cross-reactivity with naturally occurring antibodies in human sera while retaining efficient and specific cleavage of human IgG antibodies.

Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy

Copenhagen, Denmark, 13 February 2024 - Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) has today resolved on a new issue of shares with preferential rights for the Company's existing shareholders of up to DKK 51.2 million before transaction costs (the “Rights Issue"). The proceeds are intended to be used to strengthen the Company’s capital structure and secure funding for the acceleration of clinical activities, including the preparation, planning and enrolment of the first patients in a therapy phase I/IIa basket trial in various cancer types, as well as to strengthen Curasight’

Elicera Therapeutics AB (publ) Year-End Report 1 January – 31 December 2023

Fourth quarter (October-December 2023) · Operating profit/loss amounted to SEK -5,212,694 (-3,951,799). · Loss for the period amounted to SEK -4,749,222 (-3,898,340). · Cash flow from operating activities totaled SEK 3,503,148 (5,516,307). · Earnings per share before dilution totaled SEK -0.24 (-0.20). Earnings per share after dilution totaled SEK -0.24 (-0.20). · Proposed dividend of SEK 0.00 per share (0.00 for the preceding year).   Period (January-December 2023) · Operating profit/loss amounted to SEK -17,096,277 (-19,362,750). · Loss for the period

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

· Coming Phase I/IIa basket trial planned to include five select cancer indications · Study will apply Curasight’s uPAR theranostic platform approach combining diagnosis (uTRACE[®]) and therapy (uTREAT[®]) · First patients expected to be dosed in the beginning of 2025 with expected first efficacy data in 2025. Copenhagen, Denmark, 13 February 2024 - Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer

Amuse Presents Direct Integration with YouTube for Official Artist Channels

Managing music and artist content across YouTube can be challenging and tedious. To help DIY and independent artists gain control of their presence on the platform, global music company and distributor Amuse presents an automated integration with YouTube for Official Artist Channel (OAC) access. Eligible Amuse distribution users can now request their OAC with just a few clicks, merging all subscribers and content from different parts of YouTube into one convenient channel.The integration is the latest result of Amuse’s continued ambition to solve pain points for the DIY and independent

Camurus appoints Behshad Sheldon as President of Camurus Inc.

Lund, Sweden — 13 February 2024 — Camurus AB (NASDAQ STO: CAMX) today announced the appointment of Behshad Sheldon as President of Camurus Inc. and member of the company’s executive management team, starting 1 April 2024. Behshad has been a member of Camurus’ Board of Directors since 2018, contributing to Camurus’ development as a successful and profitable, commercial-stage pharmaceutical company. Behshad brings more than 25 years of experience from leading positions within the international pharmaceutical industry, including as President & CEO of Braeburn Pharmaceuticals up to 2017, and

Repurchases of shares by Attendo AB during week 6, 2024

On 9 February 2024 Attendo AB (LEI code 549300KEJDL2FNITUW65) (“Attendo”) has repurchased in total 43,382 own shares (ISIN: SE0007666110) as part of the repurchase program initiated by the Board. The repurchases form part of the repurchase program of a maximum of 16,138,659 own shares for a total maximum amount of SEK 110,000,000 that Attendo announced on 8 February 2024. The repurchase program, which runs between 9 February 2024 and 24 April 2024, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 and the Commission Delegated Regulation (EU) No 2016/

Esmaeilzadeh Holding publishes year-end report for 2023

“During the fourth quarter, we continued to consolidate and strengthen EHAB’s balance sheet, which resulted in new financing projects, structured processes, and in-depth operational work with our portfolio companies. The current economic conditions challenge the entire company group, and we are therefore positive that a majority of the portfolio continues to deliver stable financial results. EHAB’s highest priority is to position the company for long-term value creation, and we are convinced that our initiatives are taking us in the right direction.” - Saeid Esmaeilzadeh Financial

Navamedic ASA: Invitation to 2023 4th quarter presentation

Oslo, February 13, 2024 - Navamedic ASA (OSE: Nava) will be presenting its fourth quarter 2023 results on Thursday, February 15, 2024. The presentation will be held at Dronning Eufemias gate 16 in Oslo and the event will start at 08.30 CET. A link to the webcast and the presentation will be available through the Navamedic web site on the following link: https://navamedic.com/investors/financial-results/ For further information, please contact: Kathrine Gamborg Andreassen, CEO, +47 951 78 680 E-mail: kathrine@navamedic.com Lars Hjarrand, CFO, +47 917 62 842 E-mail: lars.hjarrand@

Repurchases of shares by Concentric AB during week 6, 2024

Between 5 February 2024 and 9 February 2024 Concentric AB (LEI code 5493002G9GMTKIP3PW19) (“Concentric”) has repurchased in total 19,025 own shares (ISIN: SE0003950864) as part of the repurchase program initiated by the Board. The repurchases form part of the repurchase program of a maximum of 3,519,172 own shares for a total maximum amount of SEK 150,000,000 that Concentric announced on 26 July 2023. The repurchase program, which runs between 31 July 2023 and 31 March 2024, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 and the Commission Delegated

Metso awarded a major order for concentrator plant equipment for a copper project in Chile

Metso Corporation’s press release on February 13, 2024, at 09:00 a.m. EETMetso has been awarded a major order to deliver key concentrator equipment for a copper mining project in Chile. The value of the order is approximately EUR 55 million, and it is booked in the Minerals segment’s first-quarter 2024 orders received.The Metso delivery scope consists of high-capacity Nordberg® MP1250 secondary cone crushers, MF Series[TM] vibrating screens and energy-efficient Vertimill® VTM1500 regrinding mills. For the flotation and separation circuit, Metso will supply multiple TankCell® and

New Zeta Fresh Air Helmets and Beta Art helmet designs

KEMPPI        PRESS RELEASE        13 FEBRUARY 2024       9.00 EET New Zeta Fresh Air Helmets and Beta Art helmet designs Kemppi launches lightweight helmets with maximum breathing protection and updates the popular Beta e-series welding helmets with an exciting new look. Brand new Zeta Fresh Air helmets come with a respirator for maximum breathing protection while also offering complete eye and face safety. Each model in the Fresh Air range is specifically designed for one-hand use while also offering enhanced visibility features. They also feature a lightweight, narrow design

SLP expands and extends lease agreements with existing tenant

In the beginning of 2023, the tenant Hårds Transport signed a five-year lease with SLP for an area of approximately 5,600 square meters and a short-term contract for approximately 3,800 square meters in the property Lamellen 1 in Ljungby. Now a new lease agreement is signed for additional 2,200 sqm and the short-term contract is extended to a four-year lease.The total area thus amounts to approximately 11,700 square meters, with a tenancy period until March 2028. The annual rental value amounts to SEK 5.9 m and is fully indexed. "It is pleasing for us to be a long-term partner for the

MSB strengthens Sweden’s national critical network with 5G from Ericsson

· Ericsson 5G technology crucial part of Sweden's next-generation mission-critical network infrastructure, Rakel G2 · New 5G core network will ensure fast and secure sharing of voice, data, images, and video · Implementation starts 2024The Swedish Civil Contingencies Agency (MSB) has procured a 5G core network from Ericsson (NASDAQ: ERIC) to develop Rakel G2, Sweden’s critical communications network for public safety and emergency services including national defense purposes. Police, fire brigades, emergency medical services and military organizations will be able to collaborate

Year-end report 2023

LAUNCH INITIATED IN SWEDENTHE YEAR (JAN-DEC 2023) · EBITDA SEK -25.4 million (-17.6) · Operating profit (EBIT) SEK -27.5 million (-20.2) · Profit after tax SEK -21.1 million (-15.7) · Total profit SEK -21.1 million (-15.7) · Diluted earnings per share SEK -1.33 (-2.07) · Cash and cash equivalents amounted to SEK 60.6 million (125.6) FOURTH QUARTER (OCT-DEC 2023) · EBITDA SEK -8.0 million (-4.0) · Operating profit (EBIT) SEK -8.2 million (-4.6) · Profit after tax SEK -6.4 million (-3.1) · Total profit SEK -6.4 million (-3.1) · Diluted earnings per

Transaction in Own Shares

    13 February 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |12/02/2024|+----------------------------------------------------------

Peab repeats its nine external targets on Capital Market Day

Peab repeats its nine external targets during its Capital Market Day in Stockholm today where President and CEO Jesper Göransson and the rest of Peab’s executive management present an update of the business’ current situation and strategic focus going forward. Based on the ongoing so-called phase 1 projects in construction contract operations, Peab is also communicating potential orders for a total of SEK 19 billion over the next two years.Peab is a community builder that through its four collaborating business areas and local presence can be found all over the Nordic region. This business

Initiation of share acquisitions by employees in OKEA ASA

Trondheim, 13 February 2024 In connection with the share-based bonus program in OKEA ASA (the “Company”, ticker: “OKEA”), DNB has been mandated to purchase shares in the market for an aggregate amount of up to NOK 27,890,842 in the Company on behalf of 440 employees, including primary insiders. The collective share purchase will commence today and is expected to be completed on 28 February 2024 at the latest. Shares awarded under the Company's share-based bonus program will be subject to a 12-month lock-up period from the date of purchase. All share purchases will be executed on

Vianode appoints Howard Ormonroyd as CFO, bringing extensive experience in financing large-scale materials and infrastructure projects

Oslo, Norway – 13 February 2024: Vianode, an advanced battery materials company providing sustainable anode graphite solutions, has appointed Howard Ormonroyd as CFO. As a member of the executive management team, he will focus on financing and value creation as Vianode establishes itself as a leading supplier to battery and EV value chains in North America and Europe.Ormonroyd assumes the position effective 14 February, coming from J.P. Morgan where he was an Executive & Technical Director in the Global Metals & Mining investment banking division for over 10 years. He will oversee the

Implantica announces first RefluxStop™ public tender win, paving the way for permanent reimbursement in Italy

Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, announces that Hospital Santa Croce of Moncalieri, Turin, Regione Piemonte, Italy, has won the first-ever public tender for RefluxStop™.Dr Gabriele Pozzo, Head of General Surgery at Ospedale Santa Croce of Moncalieri, Turin, successfully performed three RefluxStop™ procedures in Dec 2023. All three patients are now well recovered. His hospital has also succeeded in winning a public tender under which the hospital will be funded for the full list price for each RefluxStop™ by the public

Inside information: Preliminary information for Tokmanni Group’s full-year 2023 result and guidance for 2024

Tokmanni Group Corporation        Inside information        13 February 2024 at 9:00 amTokmanni Group Corporation publishes preliminary information on it’s financial development for full-year 2023. Based on preliminary and unaudited information, revenue was approximately EUR 1,393 million and comparable EBIT approximately EUR 99 million in 2023. The revenue and comparable EBIT for 2023 are in accordance with the guidance given earlier. Previously, Tokmanni Group expected 2023 revenue to be EUR 1,370–1,440 million. Comparable EBIT was expected to be EUR 90–110 million. Outlook for 2024

Dataloy Systems & Mizzen Digital Announce TechIntegration for Streamlined Port Cost Management

TechIntegration Partnership Boosts Maritime Efficiency Through Dataloy's And Mizzen Digital's Integrated Port Cost Management SolutionsOslo, Norway; Copenhagen, Denmark– February 13, 2024 Dataloy Systems, known for its expertise in voyage management software, has announced a new integration with Mizzen Digital, a company specialising in port cost management solutions. This collaboration underscores Dataloy Systems’ commitment to leveraging technology to streamline and improve maritime logistics operations. Building on a Legacy of Successful Integrations The integration aims to

There are no items matching the current filter
There are no more items matching the current filter
Back to top